243 related articles for article (PubMed ID: 32549090)
21. Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
Sugarman JL; Weiss J; Tanghetti EA; Bagel J; Yamauchi PS; Stein Gold L; Lin T; Martin G; Pillai R; Israel R
J Drugs Dermatol; 2018 Aug; 17(8):855-861. PubMed ID: 30124724
[TBL] [Abstract][Full Text] [Related]
22. Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin.
Tanghetti EA; Zeichner JA; Gold M; Sadick N; Cook-Bolden FE; Kircik LH; Stein Gold L; Weiss J; Tyring SK; Del Rosso JQ; Guenin E
J Dermatolog Treat; 2023 Dec; 34(1):2147391. PubMed ID: 36382987
[TBL] [Abstract][Full Text] [Related]
23. The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Moderate-to-Severe Acne Vulgaris.
Tyring SK; Kircik L; Pariser DM; Woolery-Lloyd HC; Harper JC; Bhatt V; Pillai R; Guenin E
Am J Clin Dermatol; 2020 Dec; 21(6):891-899. PubMed ID: 32886337
[TBL] [Abstract][Full Text] [Related]
24. Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.
Stein Gold L; Elewski B; Draelos Z; Jacobson A; Lin T
J Drugs Dermatol; 2020 May; 19(5):504-514. PubMed ID: 32484629
[TBL] [Abstract][Full Text] [Related]
25. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Feldman SR; Werner CP; Alió Saenz AB
J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Tazarotene Lotion, 0.045% in the Treatment of Truncal Acne Vulgaris.
Kircik L
J Drugs Dermatol; 2022 Jul; 21(7):713-716. PubMed ID: 35816073
[TBL] [Abstract][Full Text] [Related]
28. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
[TBL] [Abstract][Full Text] [Related]
29. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.
Shalita AR; Chalker DK; Griffith RF; Herbert AA; Hickman JG; Maloney JM; Miller BH; Tschen EH; Chandraratna RA; Gibson JR; Lew-Kaya DA; Lue JC; Sefton J
Cutis; 1999 Jun; 63(6):349-54. PubMed ID: 10388959
[TBL] [Abstract][Full Text] [Related]
30. Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials.
Kircik LH; Green L; Guenin E; Khalid W; Alexander B
J Dermatolog Treat; 2022 Jun; 33(4):2241-2249. PubMed ID: 34459694
[TBL] [Abstract][Full Text] [Related]
31. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
[TBL] [Abstract][Full Text] [Related]
32. Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
Stein Gold L; Kircik LH; Pariser D; Sugarman JL; Lin T; Kang R; Pillai R
J Drugs Dermatol; 2018 Aug; 17(8):863-868. PubMed ID: 30124725
[TBL] [Abstract][Full Text] [Related]
33. Tazarotene 0.045% Lotion: A Novel Retinoid Formulation.
Mohney LA; Singh R; Feldman SR
Ann Pharmacother; 2022 Oct; 56(10):1174-1180. PubMed ID: 35112585
[TBL] [Abstract][Full Text] [Related]
34. Vehicle Formulation Impacts Tolerability and Patient Preference: Comparison of Tretinoin Branded Lotion and Generic Cream.
Draelos Z; Tanghetti E; Guenin E
J Drugs Dermatol; 2022 Aug; 21(8):875-880. PubMed ID: 35946981
[TBL] [Abstract][Full Text] [Related]
35. A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne.
Mazzetti A; Moro L; Gerloni M; Cartwright M
J Drugs Dermatol; 2019 Jun; 18(6):570. PubMed ID: 31251550
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial.
Webster GF; Berson D; Stein LF; Fivenson DP; Tanghetti EA; Ling M
Cutis; 2001 Jun; 67(6 Suppl):4-9. PubMed ID: 11499329
[TBL] [Abstract][Full Text] [Related]
37. Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris.
Tanghetti E; Dhawan S; Torok H; Kircik L
Dermatol Online J; 2007 Jul; 13(3):1. PubMed ID: 18328195
[TBL] [Abstract][Full Text] [Related]
38. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups.
Harper JC; Roberts WE; Zeichner JA; Guenin E; Bhatt V; Pillai R
J Dermatolog Treat; 2020 Mar; 31(2):160-167. PubMed ID: 30935257
[No Abstract] [Full Text] [Related]
39. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.
Thiboutot D; Arsonnaud S; Soto P
J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s3-10. PubMed ID: 18575220
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.
Hebert A; Thiboutot D; Stein Gold L; Cartwright M; Gerloni M; Fragasso E; Mazzetti A
JAMA Dermatol; 2020 Jun; 156(6):621-630. PubMed ID: 32320027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
